Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mirabegron”

158 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 158 results

Early research (Phase 1)Study completedNCT01478490
What this trial is testing

To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

Who this might be right for
Pharmacokinetics of MirabegronHealthy Subjects
Astellas Pharma Inc 28
Early research (Phase 1)Study completedNCT01284868
What this trial is testing

A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.

Who this might be right for
Healthy VolunteersPharmacodynamics of Mirabegron
Astellas Pharma Inc 12
Very early researchActive Not RecruitingNCT05880862
What this trial is testing

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Who this might be right for
Urinary Bladder, OveractiveUrinary IncontinenceAccidental Falls
The University of Texas Medical Branch, Galveston 48
Large-scale testing (Phase 3)Study completedNCT02751931
What this trial is testing

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Who this might be right for
Neurogenic Detrusor Overactivity
Astellas Pharma Europe B.V. 91
Early research (Phase 1)Study completedNCT01478503
What this trial is testing

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Who this might be right for
PharmacokineticsHealthy Subjects
Astellas Pharma Inc 96
Post-approval studies (Phase 4)Study completedNCT07533565
What this trial is testing

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

Who this might be right for
CirrhosisAsthma
Kafrelsheikh University 78
Post-approval studies (Phase 4)UnknownNCT05188742
What this trial is testing

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Who this might be right for
Overactive Bladder Syndrome
Taipei Veterans General Hospital, Taiwan 180
Not applicableStudy completedNCT07018934
What this trial is testing

Alfuzosin and Mirabegron for Double-J Stent Symptoms

Who this might be right for
Ureteral Stent-Related Symptoms
University of Gaziantep 100
Post-approval studies (Phase 4)Study completedNCT04501640
What this trial is testing

Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Who this might be right for
Pharmacokinetics of MirabegronFood EffectHealthy Chinese Subjects
Astellas Pharma China, Inc. 24
Post-approval studies (Phase 4)UnknownNCT05452434
What this trial is testing

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Who this might be right for
Overactive Bladder
Peking Union Medical College Hospital 600
Large-scale testing (Phase 3)UnknownNCT03044912
What this trial is testing

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Who this might be right for
Overactive Bladder Syndrome
Buddhist Tzu Chi General Hospital 574
Not applicableWithdrawnNCT03087578
What this trial is testing

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Who this might be right for
Overactive Bladder
University Hospitals Cleveland Medical Center
Early research (Phase 1)Study completedNCT01297192
What this trial is testing

A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

Who this might be right for
Healthy VolunteersPharmacokinetics of Mirabegron
Astellas Pharma Inc 41
Testing effectiveness (Phase 2)Study completedNCT01604928
What this trial is testing

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Who this might be right for
Urinary Bladder, Overactive
Astellas Pharma Europe B.V. 260
Post-approval studies (Phase 4)UnknownNCT03251300
What this trial is testing

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Who this might be right for
Overactive Bladder Syndrome
Far Eastern Memorial Hospital 120
Post-approval studies (Phase 4)UnknownNCT05946902
What this trial is testing

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Who this might be right for
Female Patients With Overactive Bladder Syndrome
Far Eastern Memorial Hospital 150
Not applicableUnknownNCT04511273
What this trial is testing

Does Mirabegron Have a Positive Impact on Sexual Function in Females With Overactive Bladder

Who this might be right for
Females With Overactive Bladder Symptoms, Urgency & Urge Incontinence
Kasr El Aini Hospital 80
Early research (Phase 1)Study completedNCT00965926
What this trial is testing

Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Who this might be right for
Healthy VolunteerPharmacokinetics of YM178
Astellas Pharma Inc 72
Testing effectiveness (Phase 2)UnknownNCT06181591
What this trial is testing

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Who this might be right for
Overactive Bladder
Seoul National University Hospital 44
Large-scale testing (Phase 3)Study completedNCT00662909
What this trial is testing

Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Who this might be right for
Urinary Bladder, Overactive
Astellas Pharma Inc 2,149
Load More Results